Jinmatrics Secures U.S. Patent for Gene Delivery Platform 'GM-CAD1'
Jinmatrics has obtained a U.S. patent for the core technology of its gene delivery vector platform, 'GM-CAD1'.
According to Jinmatrics on October 6, GM-CAD1 is an intelligent gene delivery platform manufactured by manipulating viral vectors using artificial intelligence (AI)-based design technology. The platform has achieved enhanced safety by eliminating viral pathogenicity and the potential for proliferation within the human body. In addition, it features reduced immunogenicity of the vector itself and maximized efficiency for delivering target genes.
The GM-CAD1 vector platform induces a strong immune response in the body to the loaded target gene. This enables the effective production of antibodies against the target gene antigen and induces an immune response that selectively destroys only the target cells expressing the antigen, making it widely applicable for the development of anticancer drugs, gene therapies, and vaccines.
Previously, Jinmatrics validated the efficacy of the GM-CAD1 platform in animal therapeutic models for cervical cancer and herpes zoster. In particular, the herpes zoster vaccine demonstrated more than three times the therapeutic effect compared to existing alternatives, and in February, based on these results, Jinmatrics secured domestic patent registration for GM-CAD1.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seokjun Kim, Vice President of Jinmatrics, said, "With this newly granted U.S. patent, we have further strengthened the global intellectual property (IP) base of GM-CAD1," adding, "Moving forward, we will continue to develop a diverse range of pipelines using the core GM-CAD1 platform and will actively pursue global partnerships."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.